ALDH1L2

Across TCGA pan-cancer cohorts, ALDH1L2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALDH1L2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALDH1L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ALDH1L2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where ALDH1L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.830	0.462	<.001	26	view →
PDAC	DFS	Median	II,III,IV	0.611	0.843	.002	25	view →
CCRCC	DFS	Quartile	III,IV	0.410	0.837	.012	4	view →
UCEC	OS	Tertile	All	0.885	0.986	.049	2	view →
GBM	OS	Median	All	0.281	0.488	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ALDH1L2–LUAD (DFS)

Open the LUAD breakdown →